Esperion Stock Soars 4.57% Ahead of Investor Conferences

On August 27, 2025, Esperion's stock surged by 4.57% in pre-market trading, reflecting a strong investor sentiment towards the company's upcoming investor conferences and presentations.

Esperion Therapeutics has announced its participation in two significant investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference on September 3, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. These presentations will focus on Esperion's FDA-approved non-statin medicines and next-generation ATP citrate lyase inhibitors, which are designed to address high levels of LDL-C and cardiovascular disease risk.

The presentations will be available via live webcast on Esperion's website, with replays accessible for 90 days. This move is part of Esperion's strategy to engage with investors and healthcare professionals, showcasing their innovative pipeline and global expansion efforts. The company's success is underpinned by the CLEAR Cardiovascular Outcomes Trial, which involved nearly 14,000 patients, and their commitment to developing new medicines that address unmet patient needs.